Medicine To Market News

Medicine To Market News

Technology, Information and Media

Boston, MA 180 followers

Peer-generated and curated content for life science executives

About us

Biotech Thought Leadership Stop Searching. Start Leading Medicine to Market is your only source of peer-generated insights, breaking news, and downloadable resources to maximize your impact. Join TODAY!

Industry
Technology, Information and Media
Company size
2-10 employees
Headquarters
Boston, MA
Type
Privately Held
Founded
2020

Locations

Employees at Medicine To Market News

Updates

  • Medicine To Market News reposted this

    I've been concerned with the health of my gums for a long time. The Oralucent Pro Edition toothbrush has had a noticeable impact on the health of my gums and my visits to my hygienist have been much less painful.

    View organization page for Oralucent, graphic

    166 followers

    Gum disease and gingivitis effect 47% of people ages 30-years and older, that number sky rockets to 90% by the age of 80. Left untreated gum disease can progress into very painful and expensive to treat periodontal disease. Our goal at Oralucent is to reduce gum disease by using red- and blue-light therapy to reduce the harmful bacteria in your mouth, reduce inflammation, aid in healing the gums, and improve blood flow to the gum tissue. We want you to enjoy fresher breath, whiter teeth, and healthier gums. So, we want to share what we've learned about gum disease and the potential impact of red-light therapy in our Pro Edition light therapy sonic toothbrush. #OralHealthMatters #HealthySmileHealthyLife #GumHealthAwareness #OralCareRevolution #DentalHygiene https://lnkd.in/en3z7KWj

    Red-Light Therapy: A Potential Breakthrough for Gum Health and Gum Recession Prevention

    Red-Light Therapy: A Potential Breakthrough for Gum Health and Gum Recession Prevention

    oralucent.com

  • Considering a majority of pharma launches don't meet or exceed expectations, there is something to think about from a HCP POV. #pharmamarketing #HLTH #dpe #biotech #pharma

  • More. Pharma. Layoffs. Postpartum depression pill takes center stage as Sage Therapeutics announces major shakeup. In a bold move to sharpen its focus, Sage Therapeutics is undergoing a significant reorganization. The company plans to lay off over 165 employees, including 55% of its R&D team, while reshuffling top management positions. CFO Kimi Iguchi is set to depart, and Chris Benecchi will step into the newly created COO role. This strategic shift aims to prioritize the launch of Zurzuvae, Sage's FDA-approved postpartum depression treatment developed in collaboration with Biogen. Additionally, the company will concentrate efforts on advancing dalzanemdor, an experimental drug for Huntington's disease. While Sage anticipates a non-recurring charge of $26-28 million in Q4 2024 due to these changes, they're betting on a more streamlined approach to drive success in their key markets. #Biotech #PharmaceuticalIndustry #CorporateStrategy #MentalHealth #wearesage #weweresage

  • Medicine To Market News reposted this

    View profile for Frank F. Dolan, graphic

    Founder & CΞO of ARSΞNAL

    How much have you spent on conferences? Between tickets and travel, it can be thousands, but... ... if you sponsor, then it's ten of thousands. Yet still, most people I meet at them spend the money >>>>> but not the time <<<<< in preparing to do business there. They must be good, real good... ... to stand out when hundreds of other professionals are there hunting for the same customers. If the stakes were high, they would be more prepared, I would hope. I see this situation as a common pain point for the ambitious. Getting prepared for a conference, like #HTLH in Vegas in a few days. So, I turned to Clay for help. I'm busy, so I gathered the sponsor names. That's it. Like I said, I'm busy. Then put them in a table and... presto chango... look at all this info! I've shared the table with whomever wants it. And I will share more as we go in the brand new group we just launched about an hour ago. Please hop onboard! This tool is too good to not tell other people about (meaning people I want to win, maybe not the folks I don't think should win). Happy Claymaking! #clay #automation #enrichment #ai #freetools #skool #hlth2024 #conference https://lnkd.in/dvPQzWU3

    Conference Workflow in Clay · AI Toy Box- New Tools Weekly

    Conference Workflow in Clay · AI Toy Box- New Tools Weekly

    skool.com

  • Medicine To Market News reposted this

    View profile for Frank F. Dolan, graphic

    Founder & CΞO of ARSΞNAL

    OK, ok... thanks for the feedback. People want more examples because they are using these musings at work. So, here you go, lots of them in this edition! If this is helpful to you, please share and repost. I think we've got something here and I'd appreciate your generosity in getting this to more good people. #innovation #choicevscomparison #leadership #organizationalchange

    Choice versus Comparison

    Choice versus Comparison

    Frank F. Dolan on LinkedIn

  • Groundbreaking innovation in schizophrenia treatment just reshaped the pharmaceutical landscape, with potential ripple effects across the entire neuroscience sector. Bristol Myers Squibb's Cobenfy, targeting cholinergic receptors instead of traditional dopamine pathways, marks the first major breakthrough in decades for a condition affecting 2.8 million Americans. Industry forecasts project Cobenfy to generate a staggering $2.99 billion in sales by 2030, reflecting its game-changing potential in a global antipsychotic market set to reach $26.48 billion by 2032. This FDA approval follows BMS's strategic $14 billion acquisition of Karuna Therapeutics, signaling a renewed focus on neuroscience R&D across the pharmaceutical industry. Cobenfy's success could trigger a wave of M&A activity, with large pharma companies eyeing innovative neuroscience assets to bolster their pipelines. For investors, this development underscores the value of long-term commitments in addressing complex neurological conditions, potentially catalyzing breakthroughs in other challenging areas like Alzheimer's and depression. #pdufa FDA Neurocrine Biosciences #drugapproval #pharma #biotech

  • Medicine To Market News reposted this

    View organization page for BioDataStudio, graphic

    54 followers

    Dupixent's groundbreaking FDA approval for COPD treatment is poised to reshape a $21.8 billion market. As the first biologic therapy for COPD patients with an eosinophilic phenotype, Dupixent addresses a significant unmet need in respiratory medicine. Clinical trials demonstrated a remarkable 30-34% reduction in moderate or severe COPD exacerbations over 52 weeks. Analysts project Dupixent's COPD-specific sales could reach $6.57 billion across seven major markets by 2033. This approval contributes to Dupixent's anticipated global sales of $21.4 billion across all indications by 2029. The broader lung disease therapeutics market is expected to surge from $83.4 billion in 2023 to $152.4 billion by 2033, growing at a 6.2% CAGR. Dupixent's success may accelerate research into targeted biologics, gene therapies, and digital therapeutics for COPD. The evolving COPD treatment landscape presents new opportunities and challenges for biotech firms, investors, and healthcare providers alike. Market access and adoption will hinge on demonstrating cost-effectiveness and value proposition to payers and healthcare systems. As COPD treatment becomes more personalized, biomarker-driven approaches and precision medicine are likely to reshape the competitive landscape. File under: Sanofi Regeneron #pharma #copd #biotech #pdufa #fda #drug

  • Medicine To Market News reposted this

    View profile for Frank F. Dolan, graphic

    Founder & CΞO of ARSΞNAL

    "The moment you think uncertainty is over, you’re standing at the start of the next set of questions." A company I’m very familiar with just fired their CEO and brought in a new one. I’ve also noticed some other major leadership changes in the industry recently—and it’s shaking up entire organizations. Perhaps I'm thinking of Nike, Acadia Pharmaceuticals Inc., Axsome Therapeutics, Inc., Starbucks, or Crinetics Pharmaceuticals... ...or perhaps I'm thinking of different companies. Doesn't matter. If you’re dealing with something similar right now, I want to offer a few thoughts, especially for those leading teams through these massive shifts. Because make no mistake, when leadership changes, futures change. And here’s something you need to hear: I’m not talking to managers. 😕 This isn’t about checking boxes or maintaining status quo. ☑ Managers are stuck trying to execute the past. Leaders, on the other hand, are navigating the fog of the future. Those are my people. 👊👊👊 When uncertainty hits—whether it’s coming from external pressures or internal shifts—what matters most is how you show up as a leader. I’ve seen too many folks sit back, waiting for clarity. They want answers, they want certainty. But here’s the thing: by the time you get answers, you’re already facing the next wave of questions. You think the tough part is getting through the initial storm? Think again. Once the dust settles, the real work begins. Right now, a lot of people in your organization are spiraling. They're not just worried about their jobs—they’re juggling a thousand other personal pressures. It’s your job as a leader to recognize that and actually lead. Start by giving people grace. (credit: Angie Aldinger) You don’t know what they’re carrying, but you better believe the weight of work uncertainty just made it heavier. Your job isn’t to pretend you have all the answers. It’s to help people navigate the unknown. In Part 2, I’ll dive into the internal upheaval that comes when a new leader walks in the door and how it amplifies the anxiety across the team. Stay tuned. I'll drop that Thursday AM.

  • Did you know that a rare endocrine disorder affecting just 40-70 people per million has spawned a billion-dollar market? Welcome to the world of acromegaly treatment, where scarcity meets opportunity. With a 2023 valuation of up to $2.2 billion, this niche market is projected to grow at a CAGR of up to 8.1% by 2034. Somatostatin analogs dominate, normalizing hormone levels in 50-70% of patients. But the future is bright for innovation: over 20 companies are developing novel therapies. From antisense oligonucleotides to oral somatostatin receptor agonists, the pipeline is robust. Orphan drug designations provide lucrative incentives, but regulatory landscapes are evolving. Asia Pacific emerges as a hotspot for rapid market expansion. For investors, it's a high-stakes game of premium pricing and limited competition. As personalized medicine and AI enter the arena, the acromegaly treatment market stands on the brink of transformation. Watch companies like Crinetics Pharmaceuticals, Novartis, Ipsen and more for updates on pipelines and patient opportunities. #acromegaly #endocrinology #endo #pharma #biotech

  • In a stunning move, the Federal Trade Commission has launched a legal offensive against pharmaceutical industry giants, potentially reshaping the future of drug pricing and access. This groundbreaking lawsuit targets three major pharmacy benefit managers (PBMs) - Caremark Rx, Express Scripts, and OptumRx - alleging anticompetitive practices that have artificially inflated insulin prices. The implications are staggering: these PBMs control approximately 80% of all U.S. prescriptions, wielding unprecedented influence over drug pricing and market access. At the heart of the controversy is a "perverse drug rebate system" that has led to eye-watering price hikes, with some insulin brands seeing increases of over 1,200% in less than two decades. For life science companies, this legal action could herald a new era of pricing pressure and market access challenges, potentially catalyzing a shift towards more transparent pricing models or value-based contracting. Investors in the sector face a complex landscape of risks and opportunities, with potential market disruptions for companies reliant on high-cost drugs and emerging prospects for those developing alternative therapies or biosimilars. This lawsuit may be the tipping point for a fundamental restructuring of the pharmaceutical supply chain, signaling a future of greater transparency in pricing and formulary decisions. As the industry navigates this seismic shift, adaptability will be key. Companies and investors who can successfully pivot in this new paradigm may uncover significant opportunities for growth and value creation. #pdm #pharmacybenefitmanager CVS Caremark UnitedHealth Group Express Scripts by Evernorth Eli Lilly and Company Novo Nordisk Sanofi

Similar pages